Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

According to the network statistics, market size of China’s blood group reagent was RMB 2.55 billion in 2024, which is expected to achieve RMB 2.86 billion in 2025 with growth rate of 12.3%.

PerkinElmer said on Wednesday that it has priced an offering of senior notes totaling $2.3 billion, providing the company with funds to help complete its planned acquisition of BioLegend.

Siemens Healthineers on Thursday announced a collaboration with A1 Life Sciences to offer an evolving portfolio of PCR-based assays for the identification of SARS-CoV-2 mutations and variants.

Roche announced on Thursday that it has entered a share purchase agreement to acquire 100 percent of the outstanding shares of the TIB Molbiol Group.

On September 9, 2021, Agilent successfully delivered the first batch of SureSelect targeted capture probe products produced in China at its Hangzhou production base.

Foundation Medicine announced on Wednesday that it is collaborating with Science 37 to create a home-based clinical trial model for patients who can't travel to clinical trial sites.

Alamar Biosciences said on Wednesday that it has closed an $80 million Series B financing round, bringing its total funding to $110 million.

On September 8, 2021, Hangzhou Biotest Biotech Co., Ltd. was listed on SSE STAR Market. Stock code: 688767. The issue price is 34.55 yuan/share, and the opening price is 80.50 yuan/share.

Siemens Healthineers said Tuesday that the TüV Rheinland certification agency has certified its first products under the new European In Vitro Diagnostic Regulation.

Illumina and Merck provided more details on Tuesday about their partnership to develop and commercialize tests that gauge genetic mutations involved in homologous recombination deficiency, or HRD, and identify best responders to PARP inhibitors.

Sinopharm Foreign Trade (Beijing) Co., Ltd., subsidiary of China National Pharmaceutical Group Corporation signed the agency agreement for the “Immunocytochemical Detection Kit of p16/Ki-67” (hereinafter referred to as "p16/Ki-67”) with MXB Biotechnologies Co., Ltd., subsidiary of BSBE.